Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
127
resultados
Última actualización
26/07/2026 [07:32:00]
Resultados 25 a 50 de 127
Resumen de: WO2016167365A1
Provided is a marker for determining a mental disease, which can be used for an objective diagnosis of a mental disease. A marker for determining a metal disease, which comprises at least one enterobacterium selected from those belonging to Bifidobacterium, Lactobacillus, Lactobacillus brevis, Lactobacillus reuteri subgroup, Lactobacillus sakei subgroup, Atopobium cluster, Bacteroides fragilis group, Enterococcus, Clostridium coccoides group, Clostridium leptum subgroup, Staphylococcus, Clostridium perfringens and Enterobacteriaceae.
Resumen de: US20260140112A1
Provided herein is a peptide array comprising a plurality of flagellin peptides corresponding to highly conserved peptide regions. For example, the peptide array comprises a plurality of Lachnospiraceae flagellin peptides, which can be selected from a hinge region of Lachnospiraceae flagellin. Also provided is antibody of fragment thereof that binds to one or more of the plurality of the flagellin peptides in the peptide array. The peptide array and antibody are useful in determining an immunosignature from a biological sample from a subject. The immunosignature is useful in diagnosis of an immune-mediated disease, in monitoring progression of an immune-mediated disease, in identifying subjects susceptible to certain treatments, and in monitoring treatment response.
Resumen de: US20260142011A1
Provided herein are systems and methods for optimizing a biological therapy regimen for a subject. The subject may be a patient diagnosed with an immune mediated inflammatory disease. In some embodiments, the systems and methods may involve inputting patient data into a model to forecast a drug concentration level in a patient and establish a dosing regimen for maintaining a pre-specified threshold drug concentration level in the patient. The pre-specified threshold may be a target concentration level for effective treatment of the immune mediated inflammatory disease in the patient.
Resumen de: EP4745571A1
0001 A method for determining a mucosal disorder in a gastrointestinal tract includes: a preparation step for preparing a biological sample collected from a subject to which an endoscopic dye compound has been administered; a measurement step for measuring an amount of the endoscopic dye compound or a metabolite thereof in the biological sample; a comparison step for comparing the measured amount of the endoscopic dye compound or a metabolite thereof with a reference value; and a determination step for determining that the subject is highly likely to have a mucosal disorder in the gastrointestinal tract if the measured amount of the endoscopic dye compound or a metabolite thereof is equal to or greater than the reference value.
Resumen de: EP4744731A2
0001 The present invention relates to an antibody for treating or preventing autoimmune diseases. The antibody of the present invention comprises a heavy chain variable region set forth in SEQ ID NO: 1 and a light chain variable region set forth in SEQ ID NO: 6.
Resumen de: CN122056348A
The invention discloses application of rice bran in preparation of food or health care products with functions of relaxing bowels and promoting intestinal peristalsis, and relates to the field of functional food. According to the application, the combination of active components of unsaturated fatty acid-phenolic acid-amino acid derivatives in the rice bran is defined through systematic component analysis, richer material basis explanation is provided for the bowel relaxing effect of the rice bran, the effective concentration range and the optimal concentration of the rice bran are quantified, and a direct experimental basis is provided for product dosage design.
Resumen de: CN122060665A
The invention relates to the technical field of cell biology, in particular to a construction method of children Crohn's disease intestinal tract organoid. According to the invention, a natural immune microenvironment is established by using intestinal tissues from children patients suffering from Crohn's disease and immune cells residing in the tissues, so that the experimental limitation of insufficient peripheral blood volume of children is avoided; p-nitro branstatin is innovatively introduced into a culture system, so that the formation of organoid is effectively increased. Compared with the traditional inhibitor blebbistatin of NMII, the p-nitro branstatin has the advantages that the defects of poor solubility and poor light stability are avoided, the composition stability of the culture medium is favorably maintained, and the p-nitro branstatin is more suitable for a system which is a gas-liquid type organ and is longer in liquid change interval and needs to be cultured for a long time. The invention provides a new model for exploration of related mechanisms of children Crohn's disease and evaluation of drug efficacy.
Resumen de: CN122042980A
The invention discloses application of retin-1 in prediction of an intestinal lesion range of ulcerative colitis, and relates to the technical field of inflammatory bowel disease markers. The serum Omentin-1 level can accurately predict the intestinal lesion range of the UC patient in the active period. Therefore, the invention provides a new means for managing the dynamic change of the disease of the UC patient clinically, and has a better clinical application prospect.
Resumen de: CN122005567A
The invention belongs to the technical field of biomedicine, and particularly relates to application of ME1 in preparation of a medicine for preventing and/or treating inflammatory bowel diseases. The invention discloses an application of an ME1 inhibitor in preparation of drugs for preventing and/or treating inflammatory bowel diseases, and an application of a substance for detecting ME1 in preparation of drugs for diagnosing or detecting inflammatory bowel diseases. The action effect of ME1 * in disease treatment is evaluated through a mouse IBD model induced by dextran sodium sulfate DSS and trinitrobenzene sulfonic acid TNBS, so that a new strategy and method are provided for clinical intervention of IBD. In addition, the invention also clarifies the application of the ME1 as a high-specificity biomarker in IBD diagnosis, and further expands the comprehensive value of the ME1 in disease prevention and treatment.
Resumen de: CN122012320A
The invention discloses application of bacteroides xylanolyticum capable of promoting intestinal bacteria to produce propionic acid and a composition of the bacteroides xylanolyticum in relieving ulcerative colitis, and belongs to the technical field of microorganisms. The bacteroides xylanolyticus NSP016 disclosed by the invention can quickly utilize konjac glucomannan, and the composition of the bacteroides xylanolyticus and konjac glucomannan can improve the rise of histopathologic score of mice with ulcerative colitis, maintain the integrity of intestinal barriers, reduce the oxidative stress level and remarkably reduce the level of clinical diagnosis markers of colitis, so that the clinical diagnosis of colitis is facilitated. The effect is better than that of a clinical medicine mesalazine. The bacteroides xylanolyticum NSP016 and the composition thereof disclosed by the invention have very wide application prospects in the aspect of preparing foods, pharmaceutical compositions, health-care products or feed additives for relieving ulcerative colitis.
Resumen de: KR20240124203A
The present invention relates to a companion diagnostic biomarker composition for predicting an astragalin treatment response to inflammatory bowel disease. By confirming that the expression of stathmin or regulator of chromosome condensation 2 (RCC2) is specifically reduced in a response group having an astragalin treatment response to inflammatory bowel disease, the present invention can be used as the companion diagnostic biomarker composition for predicting an astragalin treatment response to inflammatory bowel disease.
Resumen de: CN121991171A
The invention belongs to the technical field of bioactive peptides, and provides a small red bean polypeptide for preventing and treating ulcerative colitis and application of the small red bean polypeptide, and the amino acid sequence of the small red bean polypeptide is IFNNDPNNHP. The small red bean polypeptide can significantly reduce the DAI score of a mouse with DSS colitis, relieve the shortening of the colon length of the mouse with DSS colitis and improve the erosion and ulcer degree of the colonic mucosa, and has good prevention and treatment effects on ulcerative colitis; meanwhile, the preparation method is simple and easy for industrial production; certain drug research and development and clinical application values are realized.
Resumen de: WO2026097001A2
The present disclosure is related to ex vivo methods and devices for identifying a presence of or predicting a risk for a condition in a subject, wherein the risk or condition is correlated with an oxidation-redox potential (ORP) of a biological sample obtained from the subject, such as a fecal sample. The methods and devices of the present disclosure can be used to diagnose and monitor gut microbiome health and assess the risk and/or presence of conditions such as obesity, metabolic dysfunction associated steatotic liver disease (MASLD), type 2 diabetes, hyperlipidemia, hypertension, cardiovascular disease, a gut specific condition, irritable bowel syndrome, an inflammatory bowel disease, ulcerative colitis, Crohn's disease, a Clostridium difficile infection, or any combination thereof based on an ORP of the subject's sample.
Resumen de: WO2025003436A1
The present application provides an ultrasensitive colorimetric assay as well as an early biomarker for patient monitoring and medical treatment of patients suffering from a possible mitochondrial dysfunction, inflammatory bowel disease, particularly Crohn's disease. The ultrasensitive colorimetric assay measures the level of L-citrulline in a plasma or serum sample; and when the level of L-citrulline in plasma or serum decreases or falls even below 30 µmol L-citrulline, this indicates a mitochondrial cell disorder caused by a relapse or an increase in intestinal inflammation due to a flare of Crohn's disease. A method of detecting and treating the mitochondrial dysfunction is also provided.
Resumen de: CN121971661A
The invention provides a radiopharmaceutical and application thereof, and relates to the technical field of nuclear medicine, the radiopharmaceutical provided by the invention can be used as an integrin alpha4beta7 imaging agent, and imaging diagnosis can be carried out on focuses of diseases (such as inflammatory bowel diseases or tumor diseases) related to positive expression of integrin alpha4beta7 by utilizing a PET imaging technology of nuclear medicine. A chelating part in the integrin alpha4beta7 radiopharmaceutical can be replaced by NOTA chelating agents, NODAGA chelating agents, DOTAGA chelating agents, THP chelating agents and TRAP chelating agents, and the integrin alpha4beta7 radiopharmaceutical can be used for labeling < 68 > Ga metal nuclides, < 61 > Cu metal nuclides, < 64 > Cu metal nuclides and < 177 > Lu metal nuclides, so that PET imaging and nuclide treatment of various nuclides are further realized.
Resumen de: CN121971613A
The invention provides application of ANKRD13A as a target spot in preparation of an anti-enteritis drug, relates to the technical field of biomedicine, and is technically characterized in that application of ANKRD13A as a target spot in preparation of an anti-enteritis drug is provided. According to the application, the mRNA expression level of ANKRD13A in intestinal mucosa of adult and pediatric ulcerative colitis (UC) patients is proved to be obviously lower than that of a healthy control group by analyzing a GEO public data set; an Ankrd13a gene knockout mouse model is constructed, and it is found that gene deletion in a steady state does not affect colon development and functions; after acute colitis is induced by DSS, the death rate of knockout mice is increased, the colitis susceptibility is increased, the colon is shortened, intestinal epithelium injury is aggravated, and immune cell infiltration is increased. According to the application, the key regulation effect of the ANKRD13A in ulcerative colitis is defined, an experimental basis is provided for developing the ANKRD13A as an anti-enteritis drug target and a diagnostic marker, and the related drug can be used for preventing and treating enteritis.
Resumen de: CN121955382A
The invention discloses a protein marker for differential diagnosis of intestinal extracorporeal natural killer/T cell lymphoma and application of the protein marker. The protein marker is composed of COL6A3 and MFAP2 protein. Or the protein is composed of ADAMTS4, COL6A3 and MFAP2 protein. The invention also provides application of a reagent for detecting the protein in preparation of a kit for diagnosing intestinal natural killer cell/T cell lymphoma or evaluating the occurrence risk of the intestinal natural killer cell/T cell lymphoma. According to the invention, the technical bottleneck of difficulty in pathological diagnosis caused by superficial endoscopic biopsy sample of the intestinal ENKTL is effectively solved, and ENKTL can be accurately identified from ulcerative colitis, diffuse large B-cell lymphoma and colon cancer. The method is simple and convenient to operate, the selected antibody is strong in signal and clear in background in IHC detection, a quantitative result with good repeatability and high specificity can be obtained by combining an H-score scoring system, and objectivity and accuracy of pathological diagnosis are remarkably improved.
Resumen de: CN121950604A
The invention discloses an application of intestinal Rosebaria capable of promoting intestinal bacteria to produce valeric acid and a composition of the intestinal Rosebaria in relieving ulcerative colitis, and belongs to the technical field of microorganisms. According to the intestinal Rosiberia NSP017 disclosed by the invention, the konjac glucomannan can be quickly utilized, and the composition of the intestinal Rosiberia and the konjac glucomannan can be used for improving the disease activity index and spleen enlargement of a mouse with ulcerative colitis, maintaining the integrity of an intestinal barrier, reducing the oxidative stress level, and improving the ulcerative colitis activity index and the spleen enlargement of the mouse with ulcerative colitis, so that the intestinal Rosiberia NSP017 can be used for treating ulcerative colitis. The level of a clinical diagnosis marker for colitis is remarkably reduced, the effect is superior to that of a clinical medicine mesalazine, and it is found that the intestinal Rosebawnella NSP017 can promote intestinal bacteria of mice with colitis to recover the capacity of producing valeric acid. The intestinal Rosibula sp. NSP017 and the composition of the intestinal Rosibula sp. NSP017 have very wide application prospects in the aspect of preparing foods, pharmaceutical compositions, health-care products or feed additives for relieving ulcerative colitis.
Resumen de: AU2024362918A1
This disclosure relates generally to methods for treating an inflammatory bowel disease ("IBD", e.g., Crohn's disease or ulcerative colitis) in a patient. More particularly, this disclosure relates to methods for selecting a therapy for treating a patient suffering from an IBD. In embodiments, the foregoing can also be used to assess the severity of the IBD. The predictive aspects of said methods can facilitate and expedite the identification and stratification of IBD patient populations that are responsive to treatment with a RIPK2 inhibitor. The foregoing methods can further include treating the IBD by administering a RIPK2 inhibitor to the patient.
Resumen de: US20260114804A1
0000 Disclosed herein, in some aspects, are systems and methods for determining and/or monitoring a stool condition for a subject. In some embodiments, the stool condition is based on one or more images of stool of a subject. In some embodiments, the stool condition correlates with a stool assessment comprising i) a characterization of the stool according to a plurality of characteristics, and/or ii) identifying one or more medical conditions, illnesses, and/or diseases associated with the stool. In some embodiments, the stool condition is determined using one or more Artificial Intelligence engines using a trained data set. In some embodiments, the stool condition is based on one or more stool assessments performed for one or more stools corresponding to one or more bowel movements over a period of time.
Resumen de: AU2024354463A1
The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1 A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.
Resumen de: CN121930341A
本发明提供了TL1A结合分子及其应用。具体地，本发明提供了抗TL1A单域抗体或其抗原结合片段，其能够与人和食蟹猴TL1A结合，阻断TL1A/DR3通路，但不影响TL1A与TL1A/DR3通路的天然阻断剂DcR3的结合。本发明的抗TL1A单域抗体或其抗原结合片段与TL1A的结合具有pH依赖性，更有利于在体内长期循环，延长半衰期。因此，本发明的抗TL1A单域抗体或其抗原结合片段可作为新型治疗剂，应用于免疫炎症相关疾病的治疗。
Resumen de: US20260109755A1
0000 The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.
Resumen de: CN121896348A
The invention belongs to the technical field of biological medicine, and particularly discloses application of a reagent for detecting a tsRNA molecular marker in intestinal mucosa tissue to preparation of a Crohn disease diagnostic kit, the reagent is characterized in that the tsRNA molecular marker is tRF-28-PW5SVP9N1503, the sequence of the tsRNA molecular marker is GCCGTGATAGTGGTTAGTACTCT, the reagent for detecting the tsRNA molecular marker in the intestinal mucosa tissue comprises tRF-28-PW5SVP9N1503 fluorescent quantitative PCR upstream and downstream primers, and the primer sequence of the tsRNA molecular marker in the intestinal mucosa tissue is shown in the description. The upstream primer is AATG CCGTGATCGTATAGTGGTT, and the downstream primer is TATCCTTGTTGACGACTGGTTGAC, and the downstream primer is The method has the advantages that absolute quantitative detection of target molecules can be rapidly and accurately completed only with a small amount of samples, and the method is used for early screening and identification of Crohn's disease and is high in sensitivity and specificity.
Nº publicación: CN121878075A 17/04/2026
Solicitante:
JIANGXI UNIV OF TRADITIONAL CHINESE MEDICINE
JIANGXI INST OF FASHION TECHNOLOGY
\u6C5F\u897F\u4E2D\u533B\u836F\u5927\u5B66
\u6C5F\u897F\u670D\u88C5\u5B66\u9662
Resumen de: CN121878075A
The invention belongs to the field of analytical chemistry, and provides a method for simultaneously determining 10 tryptophan metabolites through liquid chromatography-mass spectrometry, differentiated pretreatment schemes are designed aiming at different biological matrixes such as excrement, serum, colon tissue and NCM460 inflammatory cells through a liquid chromatography-tandem mass spectrometry technology, matrix interference is effectively eliminated, and the method for simultaneously determining 10 tryptophan metabolites through liquid chromatography-mass spectrometry is provided. A quantitative analysis method with high sensitivity and high selectivity is established; the method is successfully applied to an ulcerative colitis (UC) rat model and a lipopolysaccharide (LPS)-induced NCM460 inflammation model, and a technical means is provided for revealing a metabolic regulation mechanism of medicine intervention on UC; the method solves the technical problem that various metabolites in a tryptophan metabolic pathway are difficult to detect in the prior art, is suitable for metabolic mechanism research, drug intervention effect evaluation and large-scale detection of clinical samples of inflammatory bowel diseases such as UC, and provides a technical basis for systematic research of a tryptophan metabolic network.
BOPI
Sede Electrónica
